Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
12.29
-0.04 (-0.32%)
At close: Jun 1, 2026, 4:00 PM EDT
12.40
+0.11 (0.90%)
After-hours: Jun 1, 2026, 4:00 PM EDT
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $6.88M in the quarter ending March 31, 2026, with 183.16% growth. This brings the company's revenue in the last twelve months to $17.56M, up 74.84% year-over-year. In the year 2025, Tonix Pharmaceuticals Holding had annual revenue of $13.11M with 29.85% growth.
Revenue (ttm)
$17.56M
Revenue Growth
+74.84%
P/S Ratio
11.20
Revenue / Employee
$123,634
Employees
142
Market Cap
195.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.11M | 3.01M | 29.85% |
| Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
| Dec 31, 2023 | 7.77M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 151.12M |
| Q32 Bio | 53.74M |
| MediWound | 14.48M |
| Korro Bio | 3.84M |
| Milestone Pharmaceuticals | 1.78M |
TNXP News
- 3 days ago - Tonix presents data from analysis of opioid use in adults with fibromyalgia - TheFly
- 4 days ago - Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - GlobeNewsWire
- 5 days ago - Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology - TheFly
- 5 days ago - Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology - GlobeNewsWire
- 5 days ago - Tonix Pharmaceuticals Holding Slides: Investor presentation - Filings
- 6 days ago - Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia - TheFly
- 6 days ago - Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting - GlobeNewsWire
- 13 days ago - Tonix Pharmaceuticals Holding Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts